@danawalters.bsky.social
PhD in Pharmaceutical Sciences
Interested in protein misfolding disorders and inborn errors of metabolism
Climber, runner, and dog dad
Washington State and Gonzaga Alumni
Opinions are my own
Stay Curious
Interested in protein misfolding disorders and inborn errors of metabolism
Climber, runner, and dog dad
Washington State and Gonzaga Alumni
Opinions are my own
Stay Curious
Reposted
GUARDIAN study: Genomic newborn screening using dried blood spots achieved 99.6% sequencing success; 110 true positives missed by traditional screening enabled early intervention for conditions like severe combined immunodeficiency and long QT syndrome.
ja.ma/4h3ppUH
#MedSky
ja.ma/4h3ppUH
#MedSky
January 21, 2025 at 7:36 PM
GUARDIAN study: Genomic newborn screening using dried blood spots achieved 99.6% sequencing success; 110 true positives missed by traditional screening enabled early intervention for conditions like severe combined immunodeficiency and long QT syndrome.
ja.ma/4h3ppUH
#MedSky
ja.ma/4h3ppUH
#MedSky
Office colleague has pretty low productivity
January 15, 2025 at 2:05 AM
Office colleague has pretty low productivity
Reposted
🚨🎉 BREAKING NEWS: The @fda.gov has approved BridgeBio's Attruby™ (acoramidis) for the treatment of patients with transthyretin amyloid cardiomyopathy (#ATTR-CM).
Learn more: arci.org/attruby-attr...
Learn more: arci.org/attruby-attr...
FDA Approves Attruby™ (acoramidis) for the Treatment of ATTR-CM: A New Option for Patients
The FDA’s approval of Attruby is significant for patients with ATTR-CM, providing them with another effective treatment option.
arci.org
November 23, 2024 at 7:11 PM
🚨🎉 BREAKING NEWS: The @fda.gov has approved BridgeBio's Attruby™ (acoramidis) for the treatment of patients with transthyretin amyloid cardiomyopathy (#ATTR-CM).
Learn more: arci.org/attruby-attr...
Learn more: arci.org/attruby-attr...